Drugs / Iparomlimab and Tuvonralimab
Trials 1
| Phase | Registry id | Dates | Indication | Sponsor | Status | Outcome |
|---|---|---|---|---|---|---|
| Phase 2 | NCT07369986 | Mar 2026 → Dec 2027 expected | endometrial cancer | Women's Hospital School Of Medicine Zhejiang University | Not yet recruiting | No outcome recorded |
Evidence & citations 2 cited values
Every value below carries the sentence it was read from. 1 source stands behind the page.
| Field | Value | Cited text |
|---|---|---|
| Known as | Iparomlimab and Tuvonralimab | ClinicalTrials.gov intervention name — accepted as the source's own label NCT07369986 ↗ |
| Known as | QL1706 | “Iparomlimab and Tuvonralimab (QL1706)” NCT07369986 ↗ |